Arsenic trioxide in acute promyelocytic leukemia: Potion not poison

Expert Review of Anticancer Therapy

Volumn 11, Issue 9, 2011, Pages 1317-1319

  Powell, Bayard L ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

acute promyelocytic leukemia; arsenic trioxide

Indexed keywords

ANTHRACYCLINE; ARSENIC TRIOXIDE; CYTARABINE; DAUNORUBICIN; GEMTUZUMAB; MERCAPTOPURINE; METHOTREXATE; OZOGAMICIN; RETINOIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER REGRESSION; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EVENT FREE SURVIVAL; GENE FUNCTION; GENETIC MARKER; HUMAN; LEUKEMIA RELAPSE; MOLECULAR PATHOLOGY; ONCOGENE; PROMYELOCYTIC LEUKEMIA; RETINOIC ACID RECEPTOR ALPHA GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; ARSENICALS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; OXIDES;

EID: 80053048770     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.128     Document Type: Review

References (25)

1. Davey FR, Davis RB, MacCallum JM et al. Morphologic and cytochemical characteristics of acute promyelocytic leukemia. Am. J. Hematol. 30(4), 221-227 (1989). (Pubitemid 19087311)
2. Mertelsmann R, Tzvi TH, To L et al. Morphological classification, response to therapy, and survival in 263 adult patients with acute nonlymphoblastic leukemia. Blood 56(5), 773-781 (1980). (Pubitemid 11242967)
3. Stone RM Mayer RJ. The unique aspects of acute promyelocytic leukemia. J. Clin. Oncol. 8(11), 1913-1921 (1990).
4. Ventura GJ, Hester JP, Dixon DO, Khorana S, Keating MJ. Analysis of risk factors for fatal hemorrhage during induction therapy of patients with acute promyelocytic leukemia. Hematol. Pathol. 3(1), 23-28 (1989). (Pubitemid 19178055)
5. Sanz MA, Jarque I, Martin G et al. Acute promyelocytic leukemia. Therapy results and prognostic factors. Cancer 61(1), 7-13 (1988). (Pubitemid 18023103)
6. Tallman MS, Lefebvre P, Baine RM et al. Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia. J. Thromb. Haemost. 2(8), 1341-1350 (2004). (Pubitemid 40186131)
7. Larson RA, Kondo K, Vardiman JW et al. Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia. Am. J. Med. 76(5), 827-841 (1984). (Pubitemid 14142683)
8. Grignani F, Fagioli M, Alcalay M et al. Acute promyelocytic leukemia: from genetics to treatment. Blood 83(1), 10-25 (1994). (Pubitemid 24016510)
9. Zelent A. Translocation of the RARalocus to the PML or PLZF gene in acute promyelocytic leukaemia. Br. J. Haematol. 86(3), 451-460 (1994).
10. Stone RM, Maguire M, Goldberg MA et al. Complete remission in acute promyelocytic leukemia despite persistence of abnormal bone marrow promyelocytes during induction therapy: experience in 34 patients. Blood 71(3), 690-696 (1988).
11. Kantarjian HM, Keating MJ, Walters RS et al. Acute promyelocytic leukemia. M. D. Anderson Hospital experience. Am. J. Med. 80(5), 789-797 (1986). (Pubitemid 16033697)
12. Tallman MS, Andersen JW, Schiffer CA et al. All-trans-retinoic acid in acute promyelocytic leukemia. N. Engl. J. Med. 337(15), 1021-1028 (1997). (Pubitemid 27430519)
13. Fenaux P, Chastang C, Chevret S et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 94(4), 1192-1200 (1999). (Pubitemid 29380399)
14. Sanz MA, Martin G, Gonzalez M et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood 103(4), 1237-1243 (2004). (Pubitemid 38168633)
15. Shen ZX, Chen GQ, Ni JH et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89(9), 3354-3360 (1997).
16. Niu C, Yan H, Yu T et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 94(10), 3315-3324 (1999). (Pubitemid 29536124)
17. Soignet SL, Maslak P, Wang ZG et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N. Engl. J. Med. 339(19), 1341-1348 (1998). (Pubitemid 28509343)
18. Soignet SL, Frankel SR, Douer D et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J. Clin. Oncol. 19(18), 3852-3860 (2001). (Pubitemid 32880064)
19. Powell BL, Moser B, Stock W et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood 116(19), 3751-3757 (2010).
20. Gore SD, Gojo I, Sekeres MA et al. Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia. J. Clin Oncol. 28(6), 1047-1053 (2010).
21. Mathews V, George B, Lakshmi KM et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood 107(7), 2627-2632 (2006).
22. Ghavamzadeh A, Alimoghaddam K, Ghaffari SH et al. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann. Oncol. 17(1), 131-134 (2006). (Pubitemid 43033852)
23. Hu J, Liu YF, Wu CF et al. Long-term efficacy and safety of all-trans retinoic acid/ arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc. Natl Acad. Sci. USA. 106(9), 3342-3347 (2009).
24. Estey E, Garcia-Manero G, Ferrajoli A et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 107(9), 3469-3473 (2006).
25. Ravandi F, Estey E, Jones D et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J. Clin. Oncol. 27(4), 504-510 (2009).